NEW YORK (GenomeWeb News) – Quebec, Canada-based Warnex said today that its Bioanalytical Services division has purchased two TSQ Vantage mass spectrometers from Thermo Fisher Scientific, which it will use in its drug research services offerings.
Warnex President and CEO Mark Busgang said in a statement that the firm is the first clinical research organization in Canada to acquire the new TSQ Vantage system. “The increased sensitivity of this new generation of systems will allow us to detect our customers’ compounds at very low quantitation levels with great precision,” he said.
Warnex said that the TSQ Vantage system provides 10 times more sensitivity than other triple quadrupole instruments on the market.
Terms of the purchase were not disclosed.